Reduction of Postoperative Adhesions after Laparoscopic Surgery for Endometriosis by Using a Novel Anti-Fibrotic Drug Pirfenidone: A Randomized Double Blind Study

El-Halwagy, Ahmed S.; Al-Gergawy, Adel A.; Dawood, Abdelghafar S; Shehata, Ayman

doi:10.4172/2161-0932.1000422

Cited by 5 publications

(6 citation statements)

References 11 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, both in-vitro and in-vivo studies demonstrated that Sirolimus, which was approved for myeloma, induced regression of endometriotic lesions through inhibiting angiogenesis and proliferation ( 152 – 154 ). Anti-fibrotic agent Pirfenifone was proven to reduce postoperative adhesions for women with endometriosis ( 155 ). Siltuximab, an antiviral agent targeting IL-6, is one of the drug candidates for endometriosis-related infertility from the computational drug discovery ( 156 ).…”

Section: New Treatment and Target Therapymentioning

confidence: 99%

Impacts of endometrioma on ovarian aging from basic science to clinical management

Tan

Xue

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

Endometriosis is a common reproductive disorder characterized by the presence of endometrial implants outside of the uterus. It affects ~1 in 10 women of reproductive age. Endometriosis in the ovary, also known as endometrioma (OMA), is the most frequent implantation site and the leading cause of reproductive failure in affected women. Ovarian aging is one of the characteristic features of OMA, however its underlying mechanism yet to be determined. Accumulated evidence has shown that pelvic and local microenvironments in women with OMA are manifested, causing detrimental effects on ovarian development and functions. Whilst clinical associations of OMA with poor ovarian reserve, premature ovarian insufficiency, and early menopause have been reported. Moreover, surgical ablation, fenestration, and cystectomy of OMA can further damage the normal ovarian reservoir, and trigger hyperactivation of primordial follicles, subsequently resulting in the undesired deterioration of ovarian functions. Nevertheless, there is no effective treatment to delay or restore ovarian aging. This review comprehensively summarised the pathogenesis and study hypothesis of ovarian aging caused by OMA in order to propose potential therapeutic targets and interventions for future studies.

show abstract

Section: New Treatment and Target Therapymentioning

confidence: 99%

Impacts of endometrioma on ovarian aging from basic science to clinical management

Tan

Xue

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Completed, results not available Pirfenidone (4) [35] Randomized double-blind clinical trial with 210 patients -Placebo Prevention of postoperative endometriosis induced adhesions (laparoscopy before and after intervention)…”

Section: Reduction In Absolute Painmentioning

confidence: 99%

“…A therapeutic option to modulate TGF‐β is pirfenidone ( 4 ), a pyridine drug approved for the treatment of pulmonary fibrosis [55] that acts by inhibiting fibroblast activation and reducing collagen synthesis [74,75] . A double‐blind randomized controlled clinical trial of 210 endometriosis patients given oral pirfenidone showed that pirfenidone was effective at reducing endometriosis lesions, however, the side effects were too severe for it to be recommended [35] …”

Section: Molecular Targets and Active Principles In Endometriosismentioning

confidence: 99%

“…[74,75] A double-blind randomized controlled clinical trial of 210 endometriosis patients given oral pirfenidone showed that pirfenidone was effective at reducing endometriosis lesions, however, the side effects were too severe for it to be recommended. [35] Fibrosis has only recently begun to be proposed as a therapeutic target for endometriosis, and preclinical work on primary cell cultures has shone light on mechanisms leading to fibrosis. For translation to an effective therapy, it would be important to know how effectively fibrosis can be targeted at different stages of the disease, and whether it is possible to reverse or merely prevent fibrosis in endometriosis.…”

Section: Fibrosismentioning

confidence: 99%

“…Table 2 compares the respective advantages of oral and vaginal drug delivery for endometriosis therapy. After orally administered pirfenidone (4) was shown to be efficacious yet undesirable due to its adverse event profile, [35] our research group developed vaginal ovules to deliver pirfenidone locally. [111] Vaginal drug administration may lend itself well to endometriosis therapy.…”

Section: Drug Delivery Systems For Endometriosismentioning

confidence: 99%

See 2 more Smart Citations

Endometriosis, the Silent Disease: Molecular Targets, Active Principles, and Drug Delivery Systems

Teworte

Luciani

2022

Helvetica Chimica Acta

View full text Add to dashboard Cite

In this perspective, we provide a broad overview of pathophysiological processes involved in endometriosis, including the role of inflammation, fibrosis, angiogenesis, hormonal regulation, and genetic factors. For each of the functional changes involved with the etiology of the disease, we showcase a selection of active principles in various stages of preclinical and clinical development. Finally, we highlight the role of drug delivery for endometriosis, particularly oral vs. vaginal administration. In doing so, we wish to draw the community's attention to this debilitating disease and highlight the need for interdisciplinary approaches to endometriosis treatment development.

show abstract

Mucoadhesive 3D printed vaginal ovules to treat endometriosis and fibrotic uterine diseases

Teworte

Aleandri

Weber

et al. 2023

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Reduction of Postoperative Adhesions after Laparoscopic Surgery for Endometriosis by Using a Novel Anti-Fibrotic Drug Pirfenidone: A Randomized Double Blind Study

Cited by 5 publications

References 11 publications

Impacts of endometrioma on ovarian aging from basic science to clinical management

Impacts of endometrioma on ovarian aging from basic science to clinical management

Endometriosis, the Silent Disease: Molecular Targets, Active Principles, and Drug Delivery Systems

Mucoadhesive 3D printed vaginal ovules to treat endometriosis and fibrotic uterine diseases

Contact Info

Product

Resources

About